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In this month’s issue of the Journal, Rice and colleagues1report a thorough retrospective analysis of prospectively col-lected data titled “Role of Clinically Determined Depth ofTumor Invasion in the Treatment of Esophageal Carcinoma”The report has 3 major conclusions. First, the authors con-clude that clinical staging with endoscopic ultrasonography
(EUS) reliably reflects pathologic staging with an accuracy of 87%.
This observation adds to the growing body of data indicating that EUS
is the most reliable method available for the clinical staging of esoph-
ageal cancer. Second, they conclude that the tumor and nodal re-
sponses to induction therapy (chemoradiotherapy) are linked. This implies that a
benefit seen in downstaging T (tumor) indicates a similar downstaging of N (nodal
disease). They then ask the following pertinent question: Does downstaging T
portend an improved survival? The answer is partially provided in their third
conclusion that when nodal disease persists, the downstaging of the tumor does not
improve survival. This implies that even though T and N stage are linked in both
their occurrence and response to induction therapy, N is predominant and indepen-
dent of T in predicting survival. With these points made, they attempt to identify,
with clinical staging methodology, subgroups of patients who are likely to benefit
from induction therapy. Overall, the report is a movement away from the current
trend toward the belief that neoadjuvant therapy is the standard of care for all
patients with esophageal cancer. Their movement is justified by the failure of
prospective randomized clinical trials to show a convincing and consistent benefit of
neoadjuvant therapy in carcinoma of the esophagus (Table 1).2-8
In an effort to identify subgroups of patients who would benefit from induction
therapy, Rice and colleagues1 have made 3 major observations. First, they observed
that patients with clinical stage T3 N0 disease appear to have a benefit from
induction therapy (see Rice and colleagues’ Figure 2). Several concerns about their
data need to be addressed before incorporating these observations into clinical
practice. First, they have clearly shown that there is often a difference between the
clinical assessment of tumor depth (clinical T stage) and the depth of tumor invasion
on the histologic examination of the resected specimen (pathologic T stage). When
this occurs, they have chosen to explain the difference as a result of the downstaging
of the tumor by means of induction therapy when it is equally plausible that it might
be due to, at least in some cases, inaccurate initial clinical staging; that is, patients
with lesser disease might have had their disease overstaged, resulting in a perceived
but not true downstaging of the tumor by means of induction therapy. Rice and
colleagues’ Appendix Table 1 shows the overall accuracy of EUS in patients treated
with surgical intervention alone. For T3 tumors, staging errors occurred in 18 of 112
patients, with 15 (13%) having been overstaged. In most cases the overstaged
tumors were actually T1 in depth. Applying this information to the group of 28
patients depicted in Rice and colleagues’ Figure 2, one could expect that 4 patients
with apparent T3 N0 disease actually had T1 to T2 N0 disease with a potential for
better survival. This could explain the difference in survival shown in patients with
clinical stage T3 N0 disease because the difference between the expected (untreated
patients) and observed (treated patients) survival at 5 years was only 4 patients. The
second concern is that expected survival of the clinically staged T3 N0 subgroup on
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the basis of their rather convoluted statistical method is not
as good as the actuarial survival reported in other clinical
series. We and others have reported a 40% to 85% 5-year
survival in pathologic T3 N0 disease treated by means of
surgical intervention alone.9-11 These results are clearly at
odds with their current expected T3 N0 survival of 15% at
5 years, with a median survival of 18 months estimated by
means of multivariable analysis (Rice and colleagues’ Fig-
ure 2). In fact, their expected survival is worse than the
actuarial survival they reported for T3 N0 disease of 26%
with a median survival of 26 months in the Journal in
1996.12 Furthermore, their expected survival calculated for
T3 N0 disease (Rice and colleagues’ Figure 2) is worse than
that calculated for N1 disease with any T stage (Rice and
colleagues’ Figure 4). Most centers report a lower survival
with N1 disease.9-11 On the basis of our review of their data,
we fear that the model they used to estimate the expected
survival of the group undergoing surgical intervention alone
might not reflect clinical experience. Why their predictive
equation gives such a disparity is unclear. The third concern
is the criteria used to define patients for inclusion in the
clinical T3 N0 subgroup. It is possible that the benefit of
induction therapy that they have shown for clinical T3 N0
disease would have been negated by inclusion of all patients
with this stage of disease who received induction therapy
and not just those who completed therapy and went on to
surgical intervention. The usual approach in reporting mul-
timodality therapy results is to use the intention-to-treat
model. If this was done, it is possible that the number of
patients who did not undergo surgical intervention because
of death, toxicity, or progression of disease while receiving
induction therapy would outweigh any potential benefit
achieved with the combined therapy. The mortality rate
reported for induction therapy alone is as high as 7% to
10%,13-15 with toxicity or progression of disease preventing
the planned surgical intervention in another 4% to
20%.7,16,17
The second major observation made by Rice and col-
leagues1 is that patients who received induction therapy for
clinical N1 disease but who were found to have pathologic
N0 disease at resection had a survival, on the basis of their
multivariable model, that was better than that expected for
patients undergoing surgical intervention alone. The signif-
icance level of this comparison was borderline (P  .07)
and suggests that if there is a benefit to downstaging N, the
magnitude is small. The issue of clinical downstaging and
the errors induced by overstaging described above with T3
disease apply equally to patients with N1 disease. The report
by Rice and colleagues published in the Journal in 199918
showed an accuracy of 80% for EUS assessment of N1
disease. This would suggest that as many as 3 of the 14
patients receiving induction therapy for clinical N1 disease
in the current series might have been overstaged. That is,
they might have had N0 disease in the first place, with a
potential for better survival. Once again, inaccurate staging
could explain the difference in survival shown in Rice and
colleagues’ Figure 4 because the variance between the ex-
pected and observed survival at 5 years was only 2 patients.
The third major observation made by Rice and col-
leagues1 is that induction therapy might actually harm pa-
tients with clinical T1 and T2 disease when node metastases
are absent on clinical staging. This finding, we believe, is
TABLE 1. Randomized trials of neoadjuvant chemoradiotherapy followed by surgical intervention versus surgical inter-




CRT  S arm S alone
arm p-CR
Survival (median) P
valueChemotherapy Radiotherapy CRT  S S alone
Nygaard2 1992 Sq 47 C, B 35 Gy 41 NA (12mo) (12 mo) .3
2 cycles Nonconc TTE 3-y: 17% 3-y: 9% N/A
Apinop3 1994 Sq 35 C, 5-FU 40 Gy 34 26% (9.7 mo) (7.4 mo) .4
2 cycles Conc TTE 3-y: 26% 3-y: 20% N/A
Le Prise4 1994 Sq 41 C, 5-FU 20 Gy 45 10% (12mo) (12 mo) .56
2 cycles Nonconc 3-y: 19% 3-y: 14% N/A
Walsh5 1996 A 58 C, 5-FU 40 Gy 55 25% (16 mo) (11 mo) .01*
2 cycles Conc mixed 3-y: 32% 3-y: 6% .01
Bosset6 1997 Sq 143 C 37 Gy 139 26% (18.6 mo) (18.6 mo) .78
2 cycles Nonconc TTE
Urba7 2001 A 75% 50 C, V, 5-FU 45 Gy 50 28% (16.9 mo) (17.6 mo) N/A
Sq 25% 2 cycles Conc THE 3-y: 30% 3-y: 16% .15
MRC Trial8 2002 Sq 31% 400 C, 5-FU Optional 402 4% (16.8 mo) (13.3 mo)
A 66% 2 cycles 2-y: 43% 2-y: 34% .004
CRT  S, Chemoradiotherapy followed by surgical intervention; S, surgical intervention; p-CR, pathologic complete response; XRT, x-ray therapy; Sq,
squamous; C, cisplatin; B, bleomycin; TTE, transthoracic echocardiography; NS, not significant; 5-FU, 5-fluorouracil; A, adenocarcinoma; V, vinblastine;
nonconc, nonconcurrent; conc, concurrent; N/A, not available.
*See text for concerns about statistical methodology and the potential for stage bias between groups.
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their most important and valuable contribution. In this sit-
uation clinical understaging (deeper invasion than EUS
suggests) might explain some of the difference between the
observed (treated patients) and expected (untreated patients)
survivals (Rice and colleagues’ Figure 3). Rice and col-
leagues’ Appendix Table 1 shows that of the 63 patients
with clinical T1 or T2 disease, 10 (16%) had their disease
overstaged. Applying this estimate to the 11 patients ana-
lyzed in Rice and colleagues’ Figure 3, one would expect 2
patients to have had their disease understaged, with a po-
tential for poorer survival than expected for clinical T1 or
T2 tumors. Elimination of these patients with understaged
disease from the analysis would certainly improve the ob-
served survival, perhaps to as high as 30% at 5 years, but
still well below the expected survival predicted by the
authors’ multivariable model. Therefore, it seems reason-
able to conclude that induction therapy could be potentially
detrimental and should not be offered to patients with T1 or
T2 N0 disease.
A reasonable question to ask is why survival should be
compromised after induction therapy for early esophageal
cancer. The answer to this question is not clear, nor has an
explanation been offered in the article. Inferences drawn
from prospective studies on induction therapy followed by
surgical intervention might provide an explanation.7,19,20 It
has been widely accepted that although induction therapy
does not improve overall survival compared with surgical
intervention alone, the subgroup of patients who have a
complete pathologic response to induction therapy have a
better survival than those who respond less, respond not at
all, or have only surgical intervention. What is overlooked is
that patients who respond less or not at all to induction
therapy have a corresponding lower survival than the aver-
age survival for the induction therapy group as a whole and
the group undergoing surgical intervention only. It is con-
ceivable that the diminished survival is due to a delay in
surgical therapy of patients whose tumors are resistant to the
induction therapy. Delays that average more than 3 months
have been reported.21 Induction therapy might also be det-
rimental to the host immune system, increasing the oppor-
tunity for systemic progression. Consequently, in patients
with early disease, when complete surgical resection results
in a high likelihood of cure, induction therapy might result
in a poorer outcome than would have occurred with initial
surgical resection. In other words, the negative conse-
quences of delaying effective therapy or suppressing host
immune function by means of routine administration of
induction therapy might only be worthwhile in the small
subgroup of patients whose tumors are sensitive to the
induction therapy and who would not have been cured with
surgical intervention alone.
The authors have taken the first step to begin to identify
subgroups of patients who might benefit from induction
therapy, and for this they are to be congratulated. They
propose selection on the basis of EUS staging and recom-
mend induction therapy for those with clinical T3 N0 and
any N1 disease. The inherent error rate in EUS staging,
however, poses problems with this approach. Furthermore,
data exist to suggest that the very patients they propose are
likely to derive a benefit from induction therapy are the
same patients who are least likely to manifest such a re-
sponse. Law and associates22 have shown, in a prospective
trial of neoadjuvant therapy for squamous cell cancer, that
the clinical tumor stage was more advanced in nonre-
sponders than in responders, with a higher percentage of T3
tumors in the nonresponding group. Jiao and coworkers23
made a similar observation in a study with minimally inva-
sive staging. They showed that a response to induction
therapy was more likely to occur in the absence of node
metastases than when lymph node metastases were present.
In the latter situation, fewer than 15% responded. Conse-
quently, we are left with a dilemma. Most patients with
advanced disease do not respond to induction therapy but
need it. Patients with early disease are more likely to re-
spond to induction therapy but need it less and, according to
the report of Rice and colleagues,1 might be harmed.
We agree with the authors that the only solution is the
selective application of induction therapy. However, how
can we identify the responders? Rice and colleagues1 advo-
cate clinical staging with EUS. We have our doubts. Ideally,
molecular biologic characterization of the tumors will pro-
vide the answers.
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